Phase 3 Recruiting NIH
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04267848
Sites in Montana: - Community Hospital of Anaconda — Anaconda, Montana
- Billings Clinic Cancer Center — Billings, Montana
- Saint Vincent Healthcare — Billings, Montana
- Saint Vincent Frontier Cancer Center — Billings, Montana
- Bozeman Health Deaconess Hospital — Bozeman, Montana
Phase 3 Recruiting NIH
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04181060
Sites in Montana: - Community Hospital of Anaconda — Anaconda, Montana
- Billings Clinic Cancer Center — Billings, Montana
- Bozeman Health Deaconess Hospital — Bozeman, Montana
- Benefis Sletten Cancer Institute — Great Falls, Montana
- Great Falls Clinic — Great Falls, Montana
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to the usual treatment (conventional image guided radiation therapy \[IGRT\] and chemotherapy followed by immunotherapy with durvalumab or target…
Sponsor: NRG Oncology
NCT ID: NCT05624996
Sites in Montana: - Billings Clinic Cancer Center — Billings, Montana
- Bozeman Health Deaconess Hospital — Bozeman, Montana
- Benefis Sletten Cancer Institute — Great Falls, Montana
Phase 3 Recruiting Industry
The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT06561386
Sites in Montana: - Local Institution - 0308 — Bozeman, Montana
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06881784
Sites in Montana: - St. Vincent Frontier Cancer Center — Billings, Montana
Phase 2 Recruiting Network
This phase II Expanded Lung-MAP treatment trial compares how well sacituzumab govitecan alone, ivonescimab alone, or sacituzumab govitecan in combination with ivonescimab works in treating patients with non-small cell lung cancer (NSCLC) t…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT07393555
Sites in Montana: - Billings Clinic Cancer Center — Billings, Montana
- Community Medical Center — Missoula, Montana
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combinatio…
Sponsor: Inhibrx Biosciences, Inc
NCT ID: NCT04198766
Sites in Montana: - Intermountain Health Cancer Centers of Montana — Billings, Montana
Phase 1, Phase 2 Recruiting Industry
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors as a monotherapy or combined with Standard(s) of Care (SOC) or with each othe…
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06162221
Sites in Montana: - Intermountain Health - St. Vincent Frontier Cancer Center — Billings, Montana
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Montana: - Community Hospital of Anaconda — Anaconda, Montana
- Billings Clinic Cancer Center — Billings, Montana
- Bozeman Health Deaconess Hospital — Bozeman, Montana
- Benefis Sletten Cancer Institute — Great Falls, Montana
- Great Falls Clinic — Great Falls, Montana
Recruiting Academic/Other
This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies …
Sponsor: Wake Forest University Health Sciences
NCT ID: NCT06418204
Sites in Montana: - Community Hospital of Anaconda — Anaconda, Montana
- Billings Clinic Cancer Center — Billings, Montana
- Montana Cancer Consortium NCORP — Billings, Montana
- Bozeman Health Deaconess Hospital — Bozeman, Montana
- Benefis Sletten Cancer Institute — Great Falls, Montana
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Montana: - Massive Bio SYNERGY-AI site — Billings, Montana
Recruiting Academic/Other
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, h…
Sponsor: University of Nebraska
NCT ID: NCT02012699
Sites in Montana: - Bozeman Health Deaconess Hospital — Bozeman, Montana